A phase 3 multicenter, randomized, open label study for subjects with relapsed and refractory multiple myeloma (RRMM) who have previously received at least 2 prior therapies including lenalidomide and a proteasome inhibitor

  • Garcia, Alex V. Mejia (CoI)

Project: Research project

Project Details

StatusFinished
Effective start/end date1/1/21 → 1/1/24

Funding

  • Amgen